We spoke with Dongzhou Liu, Assistant Director of New Products R&D at GlaxoSmithKline (GSK), about open innovation and personalized medicine at the Executive Summit on Licensing and Innovation at the 2009 Molecular Medicine Tri-Conference in San Francisco. In contrast to Roche Diagnostics' enthusia...
This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!
Analyst Insight | June 08, 2021
Biogen's recent FDA approval for an Alzheimer's disease (AD) drug is arguably the biggest news this week in the healthcare industry. Both Biogen's and its development partner Eisai's stock prices jumped more than 50% on the announcement. Yet, many dementia experts were quick to point out that the ... Not part of subscription
News Commentary | July 08, 2021
Huntington's disease (HD) is a slow and fatal neurodegenerative disease with no cure in sight. HD is caused by a mutation in the Huntingtin gene. This also makes it the perfect candidate to address with gene therapy. However, an unsolved challenge was how to measure therapeutic efficacy before the ... Not part of subscription
News Commentary | September 17, 2021
NHS will use GRAIL's Galleri test in this study, which aims to recruit 140,000 volunteers in eight areas of England. Besides being touted as the world's first and largest clinical trial of its kind, the more important significance of this study is that it is being spearheaded by one of the largest ... Not part of subscription